Kishor Wasan, RPh, PhD, FAAPS, FCAHS, FCSPS

Advisory Board

Dr. Wasan, Director of Research and Development at iCo Therapeutics, led the development of orally-administered amphotericin-B, an anti-fungal agent previously in intravenous format exclusively. Oral AmpB (iCo-019) successfully completed Phase Ib clinical trials and is expected to commence Phase II trials for candidiasis in late 2020.  Dr. Wasan is also a Distinguished University Scholar and Adjunct Professor, Faculty of Medicine, at the University of British Columbia. He has served as the Canadian Institutes of Health Research (CIHR) University-Industry Research Chair in Pharmaceutical Development (2003-2008), received the AFPC-Pfizer Research Career Award, the American Association of Pharmaceutical Scientists Award for Outstanding Research in Lipid-Based Drug Delivery, and the Canadian Society of Pharmaceutical Sciences Leadership award for outstanding contributions to Pharmaceutical Sciences.